SERDA Therapeutics
SERDA Therapeutics is a clinical stage biopharmaceutical company focused on developing innovative solutions for wound care, particularly in the treatment of burn injuries and chronic ulcers. The company aims to provide fast and effective therapeutic debridement through its proprietary enzymatic product, SN514, which is designed to enhance healing by selectively removing necrotic tissue.
SERDA Therapeutics
Paasheuvelweg 25, 1105 BP Amsterdam, the Netherlands.
What We Do
A developmental prescription product expected to provide fast and effective wound debridement, ease of use, high stability, and low-moderate irritation potential. It contains a proteolytic enzyme that selectively digests and removes necrotic tissue and eschar from wounds, facilitating healing.
Key People
News & Updates
Completion of the first Phase 1 clinical study of SN514, a key product in their development pipeline.
Initiation of the Phase 1 clinical study of SN514, aimed at addressing major unmet clinical needs.
Completion of a € 2 million funding round to support the development of their enzymatic wound debridement product.
Submission of an Investigational New Drug (IND) application for their lead product, SN514.